688.48 USD
+0.3 (+0.04%)
688.48 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX is not valued too expensively and it also shows a decent growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IDXX was profitable.
In the past year IDXX had a positive cash flow from operations.
Each year in the past 5 years IDXX has been profitable.
In the past 5 years IDXX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 30.34%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
IDXX has a Return On Equity of 65.81%. This is amongst the best in the industry. IDXX outperforms 100.00% of its industry peers.
IDXX has a Return On Invested Capital of 40.25%. This is amongst the best in the industry. IDXX outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.84%.
The 3 year average ROIC (35.08%) for IDXX is below the current ROIC(40.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
With an excellent Profit Margin value of 24.65%, IDXX belongs to the best of the industry, outperforming 95.16% of the companies in the same industry.
IDXX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.34%, IDXX belongs to the top of the industry, outperforming 98.92% of the companies in the same industry.
In the last couple of years the Operating Margin of IDXX has grown nicely.
IDXX's Gross Margin of 61.72% is fine compared to the rest of the industry. IDXX outperforms 62.90% of its industry peers.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
IDXX has less shares outstanding than it did 5 years ago.
The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
IDXX has an Altman-Z score of 23.19. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 23.19, IDXX belongs to the best of the industry, outperforming 96.24% of the companies in the same industry.
IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.04, IDXX belongs to the top of the industry, outperforming 90.86% of the companies in the same industry.
IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
IDXX has a Debt to Equity ratio (0.53) which is in line with its industry peers.
Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 23.19 |
ROIC/WACC4.41
WACC9.12%
2.3 Liquidity
A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
The Current ratio of IDXX (1.18) is worse than 83.33% of its industry peers.
A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
IDXX has a Quick ratio of 0.87. This is amonst the worse of the industry: IDXX underperforms 81.72% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.16%, which is quite good.
Measured over the past years, IDXX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.18% on average per year.
Looking at the last year, IDXX shows a quite strong growth in Revenue. The Revenue has grown by 8.39% in the last year.
IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.12% yearly.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
IDXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.18% yearly.
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y13.81%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.18%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.60, which means the current valuation is very expensive for IDXX.
67.74% of the companies in the same industry are more expensive than IDXX, based on the Price/Earnings ratio.
IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
IDXX is valuated quite expensively with a Price/Forward Earnings ratio of 46.55.
68.82% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.6 | ||
| Fwd PE | 46.55 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than 68.82% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 73.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.47 | ||
| EV/EBITDA | 38.23 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IDXX's earnings are expected to grow with 14.13% in the coming years.
PEG (NY)3.23
PEG (5Y)3
EPS Next 2Y14.65%
EPS Next 3Y14.13%
5. Dividend
5.1 Amount
IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
688.48
+0.3 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners94.91%
Inst Owner Change-0.94%
Ins Owners0.21%
Ins Owner Change2.18%
Market Cap54.98B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80.95
Price Target783.52 (13.8%)
Short Float %2.8%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)1.34%
PT rev (3m)13.31%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)2.21%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)1.25%
Revenue NY rev (3m)1.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54.6 | ||
| Fwd PE | 46.55 | ||
| P/S | 13.19 | ||
| P/FCF | 58.47 | ||
| P/OCF | 50.53 | ||
| P/B | 35.21 | ||
| P/tB | 53.23 | ||
| EV/EBITDA | 38.23 |
EPS(TTM)12.61
EY1.83%
EPS(NY)14.79
Fwd EY2.15%
FCF(TTM)11.77
FCFY1.71%
OCF(TTM)13.63
OCFY1.98%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.23
PEG (5Y)3
Graham Number74.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 23.19 |
F-Score8
WACC9.12%
ROIC/WACC4.41
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year33.04%
EBIT Next 3Y18.01%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 54.6 and the Price/Book (PB) ratio is 35.21.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 16.89% in the next year.